Yazar "Arslan, A." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Evaluation of IL-17A expressions in high-grade glial tumors receiving radiotherapy
    (NJCPONLİNE, 2022) Karaca, Figen; Keskin, Selda; Menteş, Şükran Sibel; Okten, A. I.; Çavuş, Gülin; Arslan, A.; Usul Afşar, Çiğdem; Köksal, Fatih
    Aim: In this study, we aimed to investigate the interleukin?17A (IL?17A) levels in patients with high-grade glial tumors before receiving radiotherapy, immediately after radiotherapy, and 3 months after radiotherapy. Patients and Methods: A total of 33 patients who applied to Adana City Training and Research Hospital, Department of Radiation Oncology between December 2016 and May 2018 was included in this study. A total of three blood samples was taken from each patient to assess IL?17A levels before and after radiotherapy and 3 months after the completion of radiotherapy. Results: The differences in IL?17A levels between genders were not statistically significant. IL?17A levels progressively decreased after the radiotherapy and 3 months after the radiotherapy as compared to the levels before radiotherapy. However, this was not statistically significant. IL?17A levels in the non?surviving patients were high before and after radiotherapy as compared to the surviving ones, but this was also not statistically significant. Conclusion: As compared to the period before radiotherapy, IL?17A levels tend to decrease in the period of acute and chronic phases of radiotherapy in all patient groups.
  • Küçük Resim
    Öğe
    Using intra-articular tranexamic acid in total knee replacement surgery with and without bleeding control: a prospective randomized double blind study
    (Verduci Publisher, 2018) Arslan, A.; Görmeli, Gökay
    OBJECTIVE: To investigate the effectiveness of tranexamic acid (TA) application in two techniques: in the first one wound closure is performed before the tourniquet is released; in the second one, wound closure is performed after the tourniquet is released. PATIENTS AND METHODS: The study is conducted on four groups of patients: (1) TA + TNR (tourniquet not released) where there is no bleeding control and TA is applied after wound closure without tourniquet release; (2) TA - TNR where placebo is applied after wound closure without tourniquet release; (3) TA + TR (tourniquet released) where tourniquet is released first and TA is applied after bleeding control and wound closure; and (4) TA - TR where tourniquet release is followed by bleeding control and placebo application. RESULTS: The amount of hemorrhage in hemovac drains in each group was as follows: 217.4 +/- 99.6 (100-590) ml in the TA + TNR group; 411.6 +/- 133.7 (175-850) ml in the TA - TNR group; 291.2 +/- 89.5 (160-650) ml in the TA + TR group; and 458.2 +/- 138.6 (200-920) ml in the TA - TR group (p<0.0001). The TA + TNR group differed significantly from other groups in terms of the hemorrhage in drains. Similarly, the TA + TNR group was notably different from the TA - TNR and TA - TR groups with regard to the hemoglobin and hematocrit values. CONCLUSIONS: The study reveals that the amount of blood in hemovac drains is reduced significantly after the application of tranexamic acid to the suprapatellar space in the technique where wound closure is performed without bleeding control and before the tourniquet is released.